Huge volatility expected in Bluebird Bio on Trial Data Release
The options market is expecting huge moves tomorrow in the Bio company BLUE as the update investors on the trial data listed below. Keep strong watch there could be enormous volume in the coming days.
Phase 3 data for LentiGlobin in HGB-212 (transfusion-dependent beta thalassemia), June 14; updated Phase 1/2 data for LentiGlobin in HGB-204 (beta-thalassemia), June 14; updated Phase 3 data for LentiGlobin in HGB-207, June 14.
COMPANY PROFILE
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.
Phase 3 data for LentiGlobin in HGB-212 (transfusion-dependent beta thalassemia), June 14; updated Phase 1/2 data for LentiGlobin in HGB-204 (beta-thalassemia), June 14; updated Phase 3 data for LentiGlobin in HGB-207, June 14.
COMPANY PROFILE
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.